ISSN: 2381-8727

Journal international de l'inflammation, du cancer et de la thérapie intégrative

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

An Analysis Using Propensity Scores Reveals that Monitoring High-Risk Individuals for Pancreatic Cancer Results in Better Outcomes

Dark Clatte

Background & Aims: Improved outcomes have been reported by recent high-risk pancreatic cancer surveillance programs. This study looked at whether patients with a CDKN2A/p16 pathogenic variant diagnosed under surveillance had better outcomes for pancreatic ductal adenocarcinoma (PDAC) than those with PDAC diagnosed outside of surveillance.

Method: We compared resectability, stage, and survival in a propensity score-matched cohort using data from the Netherlands Cancer Registry between PDAC patients diagnosed under surveillance and non-surveillance patients. Endurance examinations were adapted to likely impacts of lead time.

Results: The Netherlands Cancer Registry identified 43,762 PDAC patients between January 2000 and December 2020. Based on age at diagnosis, sex, year of diagnosis, and tumor location, 151 non-surveillance patients and 31 patients with PDAC under surveillance were matched 1:15. 5.8% of patients outside of surveillance had stage I cancer, whereas 38.7% of surveillance patients had PDAC (odds ratio [OR], 0.09; (0.04–0.19), 95 percent confidence interval (CI). Overall, a surgical resection was performed on 18.7% of non-surveillance patients versus 71% of surveillance patients (OR, 10.62; 95% CI, 4.56–26.63). With a 5-year survival rate of 32.4% and a median overall survival of 26.8 months, patients on surveillance had a better prognosis than non-surveillance patients, who had a 5-year survival rate of 4.3% and a median overall survival of 5.2 months (hazard ratio, 0.31; 95% CI 0.19–0.50). Surveillance patients had significantly longer survival rates than non-surveillance patients for all adjusted lead times.

Conclusion: Compared to patients with PDAC who are not monitored, those with PDAC who are carriers of a CDKN2A/p16 pathogenic variant experience improved survival, earlier detection, and increased respectability.